Back grey_arrow_rt.gif
 
Hepatitis D (Delta)
 
null.gif
 
 
  1. ID Week: Predictors of Undetectable HDV RNA 48 Weeks After Completion of Finite Treatment With Bulevirtide and Pegylated-Interferon Alpha-2a - (10/24/24)
     
  2. ID Week: Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 144 Interim Analysis of a Phase 3 Randomized Study - (10/24/24)
     
  3. HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
     
  4. Hepatitis D Changing Context Global Prevalence - (02/10/22)
     
  5. EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
     
  6. EASL: Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: Part 2 of the REEF-D study - (06/18/24)
     
  7. EASL: Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment - (06/18/24)
     
  8. EASL HDV infection in Israel: Epidemiology and co-morbidities - (06/18/24)
     
  9. EASL Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants - (06/18/24)
     
  10. EASL The burden of chronic hepatitis delta in Italy: potential impacts and effects of bulevirtide through Cost of Illness and Cost Consequence Analysis - (06/14/24)
     
  11. EASL Healthcare Resource Utilisation and Costs of Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection Across Disease States Among Hospitalised Adults in Italy - (06/14/24)
     
  12. EASL Bulevirtide Monotherapy Lowers Risk of Decompensation But Not HCC - Mark Mascolini (06/14/24)
     
  13. EASL The underestimated burden of hepatitis D among people living with chronic hepatitis B in the Gambia - (06/14/24)
     
  14. EASL Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study - (06/14/24)
     
  15. EASL Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment - (06/14/24)
     
  16. EASL Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants - (06/14/24)
     
  17. EASL Pre- and Post-Bulevirtide Biopsies Show HDV RNA Drops in Liver Track With Drops in Blood - (06/13/24)
     
  18. EASL Pre- and Post-Bulevirtide Biopsies Show HDV RNA Drops in Liver Track With Drops in Blood - Mark Mascolini (06/13/24)
     
  19. EASL Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis - (06/13/24)
     
  20. EASL No Amino Acid Substitution in HBV Pres1, HDAg, Or NTCP Associated With Suboptimal Response to Bulevirtide in Combination With Pegylated Interferon Alfa-2a Treatment in Participants With Chronic Hepatitis Delta: Results From MYR204, a Phase 2b Study - (06/13/24)
     
  21. EASL Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301 - (06/13/24)
     
  22. EASL Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis - (06/13/24)
     
  23. EASL LONG-TERM VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY FOR UP TO 120 WEEKS: A RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (06/13/24)
     
  24. EASL Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort - (06/13/24)
     
  25. EASL Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver - (06/13/24)
     
  26. EASL Unique Characteristics and Risk of Liver-Related Events Among Individuals With Hepatitis Delta Virus Infection With and Without Concurrent Hepatitis C Virus Infection: A United States Administrative Claims Data Analysis - (06/13/24)
     
  27. EASL Anti-HDV and HDV RNA Testing Rates for Hepatitis Delta Virus Among Adult Patients in the United States - (06/13/24)
     
  28. EASL Bulevirtide efficacy and safety in chronic hepatitis D patients on liver transplant waiting list for decompensated cirrhosis and/or hepatocellular carcinoma - (06/13/24)
     
  29. EASL High frequency of liver cirrhosis in European patients with hepatitis D: First data from a large multicentre study (D-SOLVE and HDV-1000 consortia) - (06/13/24)
     
  30. EASL Rapid Reductions of HDV RNA and ALT with the Monoclonal Antibody, BJT-778: Results from a Phase 2 Study - (06/13/24)
     
  31. EASL Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program - (06/12/24)
     
  32. EASL Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta - (06/12/24)
     
  33. EASL Bulevirtide Plus pegIFNα Superior to Bulevirtide Alone for Chronic HDV - Mark Mascolini (06/12/24)
     
  34. EASL Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy - (06/12/24)
     
  35. EASL Impact of Bulevirtide Given With or Without Nucleos(t)ide Analogues on 48-Week Virologic Outcomes in Patients With Chronic Hepatitis Delta Virus Infection - (06/12/24)
     
  36. EASL Improvement in Liver Histology Is Observed in Most Patients With Chronic Hepatitis Delta After 48 Weeks of Bulevirtide Monotherapy - (06/11/24)
     
  37. EASL Bulevirtide Plus pegIFNα Superior to Bulevirtide Alone for Chronic HDV - Mark Mascolini (06/11/24)
     
  38. EASL Hepatitis Delta Virus Infection is Associated with Significantly Greater Incidence of Cirrhosis and Hepatic Decompensation in U.S. Veterans with Chronic Hepatitis B - (06/11/24)
     
  39. EASL Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D - (06/11/24)
     
  40. EASL 48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2a in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204 - (06/11/24)
     
  41. EASL: LONG-TERM VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY FOR UP TO 120 WEEKS: A RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (06/08/24)
     
  42. EASL: Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort - (06/08/24)
     
  43. DDW: HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301 - (05/21/24)
     
  44. DDW: NON-INVASIVE TESTING IN CHRONIC HEPATITIS D VIRUS (HDV) INFECTION: WHAT WORKS BEST TO RULE OUT CIRRHOSIS? - (05/21/24)
     
  45. DDW: EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY - (05/21/24)
     
  46. New WHO HBV Treatment Recommendations, HDV Too; HCC monitoring; mother-to-child HBV transmission prevention - (04/15/24)
     
  47. CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)
     
  48. CROI: Epidemiologic Burden of Hepatitis D Virus in the United States - (03/28/24)
     
  49. CROI: INCIDENCE AND OUTCOME OF HDV INFECTION IN PEOPLE WITH HIV IN THE ERA OF TENOFOVIR-CONTAINING THERAPY - (03/28/24)
     
  50. CROI: Efficacy and Safety of Bulevirtide 2 mg or 10 mg for 96 Weeks in Chronic Hepatitis Delta, Including in 2 Patients With HIV/Hepatitis B Virus/Hepatitis Delta Virus - (03/28/24)
     
  51. CROI: lntrahepatic HDV activity is fueled by integrated HBV DNA-derived HBs independently from cccDNA size/a> - (03/27/24)
     
  52. AASLD: Epidemiological and Clinical Characteristics of HBV and HDV Co-infected Patients Followed by the Canadian HBV Network - (11/20/23)
     
  53. AASLD: A 5-YEAR SNAPSHOT OF NATIONAL DELTA HEPATITIS SCREENING IN METROPOLITAN FRANCE: DELTA DESCRIBE - DATA ISSUED FROM THE FRENCH HEALTH INSURANCE - (11/20/23)
     
  54. AASLD: Baseline Characteristics of Hepatitis Delta Patients Enrolled Across Phase 2 and 3 Studies of Bulevirtide - (11/20/23)
     
  55. AASLD: Relationship Between ALT Normalization Rates and Different Virologic Response Criteria in Chronic HDV Patients Treated With Bulevirtide Monotherapy - (11/20/23)
     
  56. AASLD: The need for caregiver support in patients with hepatitis D virus infection: descriptive results from a real-world survey in Germany, Italy, Spain and the United States of America - (11/20/23)
     
  57. AASLD: Development of Antidrug Antibodies on Bulevirtide Monotherapy in Chronic Hepatitis Delta Does Not Impact Bulevirtide Efficacy, Safety, or Pharmacokinetics - (11/20/23)
     
  58. AASLD: HDV persists in human hepatocytes undergoing cell division in human liver chimeric mice but is potently inhibited by pegylated interferon-alpha treatment - (11/19/23)
     
  59. AASLD: Hepatitis Debrief at AASLD 2023 (HCV, HBV, HDV), Jennifer Price MD - (11/15/23)
     
  60. AASLD: Liver-related Complications in Patients with HDV Higher than in HBV Mono-Infected Patients: A Regional NYC-Based Assessment - (11/15/23)
     
  61. AASLD: LIVER STIFFNESS MEASUREMENT TO DETECT SEVERE FIBROSIS AND CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS D INFECTION - (11/15/23)
     
  62. AASLD: The monoclonal antibody VIR-3434 and siRNA VIR-2218 for the treatment of chronic Hepatitis D Virus: preliminary results from the Phase 2 SOLSTICE trial - (11/15/23)
     
  63. AASLD: Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta: Primary Endpoint Results from a Phase 2b Open-Label, Randomized, Multicenter Study MYR204 - (11/15/23)
     
  64. AASLD: Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses - (11/15/23)
     
  65. AASLD: Low HEPATITIS DELTA TESTING TRENDS IN A U.S. NATIONAL COHORT (2000-2022): AN ANALYSIS OF PATIENT AND PROVIDER-LEVEL PREDICTIVE FACTORS - (11/15/23)
     
  66. AASLD: Occurrence of Liver-Related Events in Individuals With Hepatitis Delta Virus: A Systematic Review - (11/15/23)
     
  67. AASLD: Burden of Hepatitis D Virus infection in Italy: interim analysis from a prospective multicentre nationwide study - (11/14/23)
     
  68. AASLD: Health Care Resource Utilization and Costs of HDV Infection vs HBV Monoinfection Across Disease States in a Hospital Records Database From Spain - (11/14/23)
     
  69. AASLD: HDV Superinfection Doubles Risk of HCC Versus HBV Infection Alone - Mark Mascolini (11/14/23)
     
  70. AASLD: National and Regional Prevalence of Hepatitis Delta Virus Among Commercially Insured Patients in the US - (11/14/23)
     
  71. AASLD: VIR-2218 and VIR-3434 Therapy Is Efficacious in Preclinical Models of Hepatitis Delta Virus Infection - (11/13/23)
     
  72. AASLD: Prevalence of Hepatitis B and D Virus Among a Nationally Representative Insured Population in the United States - (11/13/23)
     
  73. AASLD: UNDERSTANDING THE ANTIVIRAL EFFECTS OF PEGINTERFERON LAMBDA WITH AND WITHOUT RITONAVIR BOOSTED LONAFARNIB IN CHRONIC HEPATITIS D INFECTION - (11/13/23)
     
  74. AASLD: BASELINE PREDICTORS OF VIROLOGICAL AND BIOCHEMICAL RESPONSES IN HDV COMPENSATED CIRRHOTIC PATIENTS TREATED WITH BULEVERTIDE MONOTHERAPY (HEP4Di STUDY) - (11/13/23)
     
  75. AASLD: BULEVIRTIDE IN PATIENTS WITH NON-COMPENSATED LIVER CIRRHOSIS DUE TO HEPATITIS D - (11/13/23)
     
  76. AASLD: Improvement in Noninvasive Markers of Fibrosis (LSM, FIB-4, and APRI) Is Seen Over 96 Weeks of Bulevirtide Monotherapy in Chronic Hepatitis Delta Regardless of Virologic Response - (11/13/23)
     
  77. AASLD: Bulevirtide: Treatment for Hepatitis D and Beyond USA Status - (11/13/23)
     
  78. AASLD: No Detectable Resistance to Bulevirtide Monotherapy Through 96 Weeks Treatment in Patients With Chronic Hepatitis Delta - (11/13/23)
     
  79. EACS: HDV Prevalence 16% in French Group With HBV and HIV - Mark Mascolini (10/26/23)
     
  80. IAS: Hepatitis delta and liver disease among people living with hepatitis B in Senegal - (08/14/23)
     
  81. EASL: Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States - (07/05/23)
     
  82. EASL: Impact of the anti-HDV reflex testing on the reduction of hepatitis D burden in Spain - (07/05/23)
     
  83. EASL: Low coverage of hepatitis D virus testing in individuals with HIV and HBV in the Netherlands (ATHENA): a retrospective, cross-sectional and longitudinal study - (07/05/23)
     
  84. EASL: Prevalence (15%) and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat'AIDS (French) cohort - (07/05/23)
     
  85. EASL: An international coalition to eliminate hepatitis B virus (ICE-HBV) survey confirms inadequate HBV/HDV screening and diagnosis diminishing elimination targets in resource limited settings - (07/05/23)
     
  86. EASL: Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease - (07/05/23)
     
  87. EASL: Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D - (07/05/23)
     
  88. EASL: Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network (HDIN) - (07/03/23)
     
  89. EASL: Fast Response to REP 2139-Mg in 3 With HDV/HBV and Decompensated Cirrhosis - Mark Mascolini (06/30/23)
     
  90. EASL: Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study - (06/30/23)
     
  91. EASL: Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical Trials and Real-World Data - (06/30/23)
     
  92. EASL: Population Adjusted Prevalence of Hepatitis Delta Virus in 21 Countries and Territories - (06/29/23)
     
  93. EASL: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D - (06/29/23)
     
  94. EASL: Lonafarnib With Ritonavir Slows HDV in 48-Week Placebo Trial - Mark Mascolini (06/29/23)
     
  95. EASL: HDV Full Genome Sequencing and Sensitive HBV Genotyping from a Large Cohort of HBV/HDV Co-infected Patients - (06/29/23)
     
  96. EASL: The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: Descriptive results from a cross-sectional study across Italy, Germany, Spain and the US - (06/29/23)
     
  97. EASL: Qualitative interviews to assess the impact of chronic hepatitis delta virus infection on health-related quality of life in untreated patients from the US, Italy, Spain, and Germany - (06/29/23)
     
  98. EASL: Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection - (06/29/23)
     
  99. EASL: Hepatitis Delta Treatment Utilization in the United States: An Analysis of Commercially Insured Adults With Hepatitis Delta Virus Infection - (06/29/23)
     
  100. EASL: Significantly Higher Clinical and Economic Burden Following Diagnosis of Hepatitis Delta Virus Infection Among Commercially Insured Adults With Chronic Hepatitis B in the United States - (06/29/23)
     
  101. EASL: Healthcare Resource Use and Costs Associated With Hepatitis Delta Virus Infection Compared With Hepatitis B Virus Monoinfection Among Commercially Insured Patients in the US - (06/29/23)
     
  102. EASL: Increased Baseline Comorbidity Burden Among Commercially Insured Patients With Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection in the United States - (06/29/23)
     
  103. EASL: Increased Baseline Comorbidity Burden Among Commercially Insured Patients With Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection in the United States - (06/26/23)
     
  104. EASL: A Retrospective Observational Cohort Study of Liver-Related Events Among Patients With Hepatitis B Virus Infection With and Without Hepatitis Delta Virus Infection - (06/26/23)
     
  105. EASL: Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta - (06/26/23)
     
  106. EASL: HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. - Mark Mascolini (06/26/23)
     
  107. EASL: HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort - (06/26/23)
     
  108. EASL: Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study - (06/26/23)
     
  109. EASL: Patients With Chronic Hepatitis Delta Virus Infection Have Higher Risk of Disease Progression Than Chronic Hepatitis B Virus Monoinfection-Results From a Spanish National Hospital Database - (06/26/23)
     
  110. EASL: Stopping Bulevirtide After Long-Term HDV Control Appears Safe With Close Monitoring - Mark Mascolini (06/26/23)
     
  111. EASL: SIGNIFICANT IMPROVEMENT OF NON-INVASIVE FIBROSIS TESTS IN HDV COMPENSATED CIRRHOTIC PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION TREATED WITH BLV MONOTHERAPY UP TO 96 WEEKS - (06/26/23)
     
  112. EASL: VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED COMPENSATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY: THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (06/26/23)
     
  113. EASL: Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C - (06/26/23)
     
  114. HBV/HDV Debrief at Global Hepatitis Summit 2023 - Markus Cornberg - (05/08/23)
     
  115. Updated Prevalence of Chronic Hepatitis B and Hepatitis Delta Infection Among Foreign-Born Individuals in the United States (Global Hepatitis Summit 2023, Paris April 28) - (05/01/23)
     
  116. Updated Prevalence of Chronic Hepatitis B and Hepatitis Delta Infection Among Foreign-Born Individuals in the United States (Global Hepatitis Summit 2023, Paris April 28) - (04/29/23)
     
  117. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients - (04/29/23)
     
  118. CROI: HEPATITIS DELTA INFECTION AMONG PERSONS LIVING WITH HIV - (04/10/23)
     
  119. Bulevirtide+PegIFN HBsAg response - (04/09/23)
     
  120. The number of new cases and deaths from liver cancer could rise by >55% by 2040. Global burden of primary liver cancer in 2020 and predictions to 2040 - (04/09/23)
     
  121. Hepatitis delta infection among persons living with HIV in Europe - (04/09/23)
     
  122. HDV Reflex Testing Increased 5-Fold the Absolute Numbers of Hepatitis D Cases - (05/09/23)
     
  123. CROI: BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)
     
  124. Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States - (01/24/23)
     
  125. Hepatitis D (Delta) Course Review: Conference Reports: USA/Global Prevalence, Mortality-HCC Impact, PWIDs, Treatment, Screening, Patient Support - (01/13/23)
     
  126. Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy - treatment duration 8-14 years - (12/29/22)
     
  127. Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks EASL 2022 - (12/29/22)
     
  128. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension - (12/12/22)
     
  129. AASLD: Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/15/22)
     
  130. AASLD: Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection - (11/14/22)
     
  131. AASLD: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/14/22)
     
  132. AASLD: Impact of Reflex Testing on the Delta Hepatitis Disease Burden in France - (11/14/22)
     
  133. AASLD: Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/14/22)
     
  134. AASLD: OVERCOMING BARRIERS TO CARE FOR DELTA INFECTED PATIENTS - (11/14/22)
     
  135. AASLD: Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program - (11/14/22)
     
  136. AASLD: Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program - (11/11/22)
     
  137. AASLD: Extension of Bulevirtide Monotherapy to 72 Weeks in HDV Patients with Compensated Cirrhosis: Efficacy and Safety From the Italian Multicenter Study (HEP4Di) Interim Analysis - (11/11/22)
     
  138. AASLD: HDV Patient Perspective: The Impact of Disease and Current Unmet Needs - (11/10/22)
     
  139. AASLD: Bulevirtide, with or without peg- interferon, in HDV infected patients in a real-life setting. two-year results from the French multicenter early access program - Mark Mascolini (11/09/22)
     
  140. AASLD: Benefit of regular screening for hepatitis delta and subsequent cirrhosis among chronic hepatitis B carriers - (11/09/22)
     
  141. AASLD: Estimating Hepatitis Delta Prevalence Among High-Risk Populations (HIV, MSM, PWID) in the United States: A Systematic Review - (11/09/22)
     
  142. AASLD: Hep D Rate 9% in Tested California Safety-Net Group (immigrants, ethnic minorities) With HBV - Mark Mascolini (11/09/22)
     
  143. AASLD: Hep D Rate 9% in Tested California Safety-Net Group (immigrants, ethnic minorities) With HBV - Mark Mascolini (11/09/22)
     
  144. AASLD: Bulevirtide Monotherapy Is Safe and Well Tolerated in Patients With Chronic Hepatitis D (CHD): An Integrated Safety Analysis of 48-Week Data - (11/09/22)
     
  145. AASLD: The Delta Delta: Gaps in Screening Patterns, Patient Assessment and Clinical Outcomes in Hepatitis D Virus Infection - (11/09/22)
     
  146. AASLD: HDV Prevalence Ranges Widely in US High-Risk Groups: Newer Data Needed - Mark Mascolini - (11/09/22)
     
  147. AASLD: CURE OF HEPATITIS DELTA INFECTION FOLLOWING 3 YEARS OF BULEVIRTIDE MONOTHERAPY IN A PATIENT WITH COMPENSATED ADVANCED CIRRHOSIS - (11/08/22)
     
  148. AASLD: Efficacy of Bulevirtide as Monotherapy for Chronic Hepatitis D (CHD): Week-48 Results From an Integrated Analysis - (11/04/22)
     
  149. AASLD: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/04/22)
     
  150. AASLD: Population adjusted prevalence of hepatitis Delta virus in 16 countries and territories - (11/04/22)
     
  151. AASLD: HDV Load Drops, Liver Markers Improve With Bulevirtide for 48 Weeks - Mark Mascolini (11/04/22)
     
  152. AASLD: BARRIERS TO HEPATITIS DELTA SCREENING: THE POINT OF VIEW OF FRENCH BIOLOGISTS - (11/04/22)
     
  153. Time for universal screening for hepatitis D - A study describing screening patterns, characteristics, and outcomes of hepatitis D virus infection - (11/03/22)
     
  154. Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus - (10/29/22)
     
  155. ID Week: Hepatitis D Virus and Hepatitis B Virus Epidemiology in Utah - (10/24/22)
     
  156. HDV/HBV+ Immigrants in USA - (10/03/22)
     
  157. HDV Prevalence in USA - (10/03/22)
     
  158. High HDV rates Among PWID - (09/29/22)
     
  159. Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection - (09/29/22)
     
  160. HBV Meeting Paris: Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 - (09/26/22)
     
  161. EASL: Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers - (07/18/22)
     
  162. EASL: Compassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV coinfection - (07/21/22)
     
  163. EASL: Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience - (07/21/22)
     
  164. EASL: Improvement of liver-stiffness in HBV/HDV-coinfected patients treated with Bulevirtide - (07/21/22)
     
  165. EASL: Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022 - (07/11/22)
     
  166. EASL: Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France - (07/08/22)
     
  167. EASL: Provider Factors Shaping Hepatitis Delta Screening - (07/08/22)
     
  168. EASL: Validation of an internal hepatitis D virus RNA Quantitative assay: Developing an assay suitable for global clinical application and clinical trials assessment - (07/08/22)
     
  169. EASL: Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of Phase 3 D-LIVR study. - (07/06/22)
     
  170. EASL: Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection - Insights from the D-LIVR trial - (07/06/22)
     
  171. EASL: Peg-Lambda HDV-RNA Kinetics Math Modeling LIMT-1 Study - (07/06/22)
     
  172. EASL: Rising Clinical and Economic Burden Among Hepatitis D Patients Who Attended Spanish Hospitals - (07/02/22)
     
  173. EASL: Impact of Patient-Related Factors on the Pharmacokinetics of Bulevirtide - (07/02/22)
     
  174. EASL: Polymorphic Analysis of Bulevirtide Sequence in preS1 of Large HBsAg Across HBV Genotypes A-H - (07/02/22)
     
  175. EASL: Integrated Safety Analysis of 24-Week Data From Three Phase 2 and One Phase 3 Clinical Trial of Bulevirtide Monotherapy Given at 2- or 10-mg Dose Level for Treatment of Chronic Hepatitis Delta - (07/02/22)
     
  176. EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (07/02/22)
     
  177. EASL: Mathematical modeling of HDV RNA kinetics suggests high peginterferon lambda efficacy in blocking viral production: Insights from the LIMT-1 study - (07/02/22)
     
  178. EASL: Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States - (07/02/22)
     
  179. EASL: Hepatitis Delta Management in the United States: An Analysis Of All-Payer Claims Database - (07/02/22)
     
  180. EASL: Healthcare Resource Utilization and Costs of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Database - (07/02/22)
     
  181. EASL: One Third With HDV Respond to Bulevirtide Monotherapy Through 24 Weeks (2 & 10 mg) - Integrated Analysis from 2 Phase 2 & 1 Phase 3 Trials - Mark Mascolini - (07/01/22)
     
  182. EASL: Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)
     
  183. EASL: EASL 2022 HBV, HDV Wrap-Up - (06/27/22)
     
  184. EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (06/27/22)
     
  185. EASL: Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)
     
  186. EASL: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)
     
  187. EASL: Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)
     
  188. EASL: Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide -Results of a "real world study" - (06/25/22)
     
  189. EASL: No Detectable Resistance to Bulevirtide in Participants With Chronic Hepatitis D Through 24 Weeks of Treatment - (06/25/22)
     
  190. EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
     
  191. EASL: Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta - Mark Mascolini (06/24/22)
     
  192. Global Hepatitis D 37% Prevalence in IVDUs - (06/14/22)
     
  193. About the Phase 3 D-LIVR Study: oral Lonagarnib/rtv +/- Peg-Lambda 48 weeks - (06/13/22)
     
  194. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection - (06/08/22)
     
  195. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial - (06/07/22)
     
  196. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients - (06/07/22)
     
  197. PREVALENCE OF HEPATITIS DELTA VIRUS (HDV) INFECTION IN THE UNITED STATES: RESULTS FROM AN ICD-10 REVIEW - 25% of HDV in USA is In NYC (Bklyn, Bronx) & NYC Suburb - (06/06/22)
     
  198. A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (05/31/22)
     
  199. Treatment for hepatitis delta virus with the prenylation inhibitor lonafarnib: It's getting closer Editorial - (05/31/22)
     
  200. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study - (05/31/22)
     
  201. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease - (05/31/22)
     
  202. Lonafarnib-A new member of the Delta Force? Editorial - (05/27/22)
     
  203. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis - (05/27/22)
     
  204. Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV - (05/27/22)
     
  205. HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
     
  206. Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta - (05/26/22)
     
  207. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes - (05/26/22)
     
  208. Hepatitis D Changing Context Global Prevalence - (02/10/22)
     
  209. Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta - (12/10/21)
     
  210. AASLD: Hepatitis D Delta Overview; New AASLD 2021 Treatment Studies (12/06/21)
     
  211. AASLD: Hepatitis D (Delta) at AASLD 2021 (12/06/21)
     
  212. AASLD: EFFICACY OF LONG-TERM TREATMENT OF CHRONIC HEPATITIS D PATIENTS WITH BULEVIRTIDE - RESULTS OF A "REAL WORLD" STUDY (11/23/21)
     
  213. AASLD: HDV Hospital Admissions Rare-But Sometimes Severe-in United States - Mark Mascolini (11/20/21)
     
  214. AASLD: MOLECULAR AND CLINICAL EPIDEMIOLOGY OF HEPATITIS D VIRUS INFECTION IN CANADA - (11/19/21)
     
  215. AASLD: Low adherence to guidelines recommendations for hepatitis D testing in HBsAg-positive patients leads to high undiagnosis rates - (11/19/21)
     
  216. AASLD: Hepatitis D-Associated Hospitalizations in the United States: 2010-2018 - (11/19/21)
     
  217. AASLD: Over 90% of Clinicians Ignore EACS Hep D Screening Advice - Mark Mascolini (11/19/21)
     
  218. AASLD: Safety and Efficacy of 2 mg Bulevirtide in Patients with Chronic HBV/HDV Co-Infection: First Real-World Results - (11/17/21)
     
  219. AASLD: Prevalence and Characteristics of Hepatitis Delta in the United States: an Analysis of All-Payer Claims Databases - (11/17/21)
     
  220. AASLD: ETHNIC VARIATIONS IN CLINICAL PRESENTATION AND TREATMENT ELIGIBILITY FOR HEPATITIS DELTA VIRUS INFECTION AT A US REFERRAL CENTER - (11/17/21)
     
  221. AASLD: Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301) - (11/16/21)
     
  222. AASLD: HDV seropositivity was common amongst HBsAg+ women enrolled in WIHS. 26 (22%) of the 117 HBsAg+ women were HDV seropositive - (11/12/21)
     
  223. Safety and effectiveness of up to 3 years- bulevirtide monotherapy in patients with HDV-related cirrhosis - (10/25/21)
     
  224. EASL: Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta: 24 Weeks Interim Data of MYR204 Phase 2b Study - Mark Mascolini (06/27/21)
     
  225. EASL: Bulevirtide With or Without PEG-IFN Shows 24-Week Activity Against Hep D - Mark Mascolini (06/27/21)
     
  226. EASL: Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study - (06/24/21)